Syndax Pharmaceuticals, Inc. (SNDX)
20.68
-0.10
(-0.48%)
USD |
NASDAQ |
Sep 03, 16:00
20.68
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Cash from Investing (Quarterly) : -16.91M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -16.91M |
| March 31, 2026 | 38.39M |
| December 31, 2025 | 81.58M |
| September 30, 2025 | 72.43M |
| June 30, 2025 | 41.89M |
| March 31, 2025 | 94.14M |
| December 31, 2024 | -268.97M |
| September 30, 2024 | 86.85M |
| June 30, 2024 | 61.75M |
| March 31, 2024 | -99.40M |
| December 31, 2023 | -16.29M |
| September 30, 2023 | 40.08M |
| June 30, 2023 | 73.91M |
| March 31, 2023 | 19.92M |
| December 31, 2022 | -137.63M |
| September 30, 2022 | -6.793M |
| June 30, 2022 | -49.95M |
| March 31, 2022 | 8.182M |
| December 31, 2021 | -59.96M |
| September 30, 2021 | 26.63M |
| June 30, 2021 | 21.68M |
| March 31, 2021 | -29.23M |
| December 31, 2020 | -64.14M |
| September 30, 2020 | 19.28M |
| June 30, 2020 | -78.61M |
| Date | Value |
|---|---|
| March 31, 2020 | -19.05M |
| December 31, 2019 | 6.596M |
| September 30, 2019 | 12.36M |
| June 30, 2019 | -18.93M |
| March 31, 2019 | 12.75M |
| December 31, 2018 | 15.96M |
| September 30, 2018 | 3.508M |
| June 30, 2018 | 19.28M |
| March 31, 2018 | 12.64M |
| December 31, 2017 | 1.55M |
| September 30, 2017 | 6.92M |
| June 30, 2017 | -36.56M |
| March 31, 2017 | 11.01M |
| December 31, 2016 | 21.33M |
| September 30, 2016 | 8.15M |
| June 30, 2016 | -0.622M |
| March 31, 2016 | -47.14M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 2.536M |
| March 31, 2014 | 1.452M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | 109.43M |
| Kura Oncology, Inc. | 92.21M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -30.27M |
| Cash from Financing (Quarterly) | 252.77M |
| Free Cash Flow | -220.87M |
| Free Cash Flow Per Share (Quarterly) | -0.3406 |
| Free Cash Flow to Equity (Quarterly) | -274.33M |
| Free Cash Flow to Firm (Quarterly) | -17.64M |
| Free Cash Flow Yield | -12.16% |